Follow
Surendra CHAUDHARY
Surendra CHAUDHARY
Harvard Medical School
Verified email at hms.harvard.edu
Title
Cited by
Cited by
Year
Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study
A Sharma, AD Dwary, BK Mohanti, SV Deo, S Pal, V Sreenivas, V Raina, ...
Journal of Clinical Oncology 28 (30), 4581-4586, 2010
3492010
Lactobacillus brevis CD2 lozenges reduce radiation-and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study
A Sharma, GK Rath, SP Chaudhary, A Thakar, BK Mohanti, S Bahadur
European journal of cancer 48 (6), 875-881, 2012
1462012
Modified gemcitabine and oxaliplatin or gemcitabine+ cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial
A Sharma, BK Mohanti, SP Chaudhary, V Sreenivas, RK Sahoo, ...
European Journal of Cancer 123, 162-170, 2019
492019
Lactobacillus brevis CD2 lozenges prevent oral mucositis in patients undergoing high dose chemotherapy followed by haematopoietic stem cell transplantation
A Sharma, T Tilak, S Bakhshi, V Raina, L Kumar, SP Chaudhary, ...
Esmo Open 1 (6), e000138, 2016
452016
A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer
L Goyal, SP Chaudhary, EL Kwak, TA Abrams, AN Carpenter, BM Wolpin, ...
Investigational New Drugs 38, 1533-1539, 2020
172020
Final results of a phase III randomized controlled trial comparing modified gemcitabine+ oxaliplatin (mGEMOX) to gemcitabine+ cisplatin in management of unresectable gall …
A Sharma, NK Shukla, SP Chaudhary, R Sahoo, BK Mohanti, SVS Deo, ...
Journal of Clinical Oncology 34 (15_suppl), 4077-4077, 2016
72016
Resection of NAFLD/NASH-related hepatocellular carcinoma (HCC): clinical features and outcomes compared with HCC due to other etiologies
S Pal Chaudhary, S Reyes, ML Chase, A Govindan, L Zhao, J Luther, ...
The oncologist 28 (4), 341-350, 2023
52023
Concomitant chemoradiation using weekly cisplatin for advanced squamous cell carcinoma of head and neck: Experience from a tertiary cancer center in India.
A Sharma, BK Mohanti, A Thakar, SP Chaudhary, S Bhasker, S Bahadur, ...
Journal of Clinical Oncology 29 (15_suppl), 5548-5548, 2011
52011
Final results of a phase II/III, randomized, double blind, placebo-controlled study to investigate the efficacy of a high potency multistrain probiotic, on chemotherapy induced …
A Sharma, SP Chaudhary, V Raina, NK Shukla, V Sreenivas, S Prakash, ...
Annals of Oncology 29, viii755, 2018
42018
Final results of a phase II/III, randomized, double blind, placebo-controlled study to investigate the efficacy of a high potency multistrain probiotic, on chemotherapy induced …
A Sharma, SP Chaudhary, V Raina, NK Shukla, V Sreenivas, S Prakash, ...
Annals of Oncology 29, viii755, 2018
42018
Immunoproliferative small intestinal disease: a report of 6 cases
B Biswas, A Sharma, GK Makharia, S Thulkar, S Arava, A Bahl, ...
Tropical Gastroenterology 35 (4), 269-272, 2015
42015
A phase II/III, randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic VSL# 35 (R), on chemotherapy-induced diarrhoea in cancer patients …
A Sharma, SP Chaudhary, V Sreenivas, S Prakash, V Raina, NK Shukla
European Journal of Cancer 49, S273-S273, 2013
42013
A pilot study of efficacy of Lactobacillus cd2 lozenges in preventing high-dose chemotherapy induced oral mucositis in patients undergoing haematopoietic stem cell transplantation
A Sharma, T Tvsvgk, V Raina, L Kumar, S Bakhshi, SP Chaudhary, ...
Blood 120 (21), 4500, 2012
42012
Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial.
BC Cho, JS Lee, YL Wu, I Cicin, MC Dols, MJ Ahn, K Cuppens, R Veillon, ...
Journal of Thoracic Oncology: Official Publication of the International …, 2023
32023
Phase 1 trial of first-line bintrafusp alfa in combination with other anticancer therapies in patients (pts) with locally advanced or advanced cervical cancer.
A Oaknin, SA Ghamande, Y Kasamatsu, M Gil-Martin, EJ Diver, G Jehl, ...
Journal of Clinical Oncology 40 (16_suppl), 5528-5528, 2022
22022
Phase 1 trial of first-line bintrafusp alfa in patients with locally advanced or persistent/recurrent/metastatic cervical cancer
A Oaknin, SA Ghamande, Y Kasamatsu, M Gil-Martin, JF Grau-Bejar, ...
Clinical Cancer Research, 2024
12024
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
BC Cho, JS Lee, YL Wu, I Cicin, MC Dols, MJ Ahn, K Cuppens, R Veillon, ...
Journal of Thoracic Oncology 18 (12), 1731-1742, 2023
12023
465 Bintrafusp alfa in combination with chemotherapy in patients with stage IV NSCLC: safety and pharmacokinetic results of the INTR@ PID LUNG 024 study
C Rolfo, L Greillier, R Veillon, F Badin, F Ghiringhelli, N Isambert, ...
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021
12021
917 Phase 1b trial of first-line bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, plus chemotherapy with or without bevacizumab in cervical cancer
A Oaknin, M Gil-Martin, E Diver, G Jehl, SA Gleicher, S Chaudhary, ...
International Journal of Gynecologic Cancer 31 (Suppl 3), 2021
12021
Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers
Oncologist, 2020
12020
The system can't perform the operation now. Try again later.
Articles 1–20